Skip to main content
    M

    Moderna Inc (MRNA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $206.80
    -8.47 (-3.93%)

    Market Cap: $87.10B

    Last updated: Nov 17, 2026 at 4:55 PM ET

    Moderna Inc (MRNA) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Moderna (MRNA) has a market cap of $87.10B and an enterprise value of $89.46B. It kept -110.46% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 2.70% above the market cap, as debt exceeds cash.

    Market Cap$87.10B
    Enterprise Value$89.46B
    Latest price (Nov 17, 2026)$206.80

    Key Dates

    The next earnings report is expected on Feb 11, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 11, 2027 (expected)
    Last Earnings DateNov 6, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.75% in the quarter ended Sep 30, 2026 and grew 2.06% a year over 2 years.

    Shares Outstanding401.00M
    Shares Change (YoY)+2.82%
    Shares Change (QoQ)+0.75%
    Share Count Growth (2Y CAGR)+2.06%

    Valuation Ratios

    Sales and book value multiples are 32.8x and 12.1x. Its year-end P/S ranged from 3.7x to 107.8x from 2018 to 2025.

    P/S Ratio32.8x
    Forward P/S36.1x
    P/B Ratio12.1x

    Valuation history and multiples

    Price Statistics

    The stock is up 734.88% over 52 weeks and trades 1.18% above its 50-day average.

    Beta (1Y)2.32
    52-Week Change+734.88%
    1-Month Change-8.85%
    3-Month Change+18.59%
    6-Month Change+352.32%
    5-Year Change-35.77%
    Total Return (1Y)+734.88%
    Total Return (3Y CAGR)+39.33%
    Total Return (5Y CAGR)-3.83%
    Return vs SPY (1Y)+718.30%
    Max Drawdown (1Y)-34.16%
    Max Drawdown (3Y)-86.58%
    Sharpe Ratio (1Y)1.63
    Correlation with SPY (1Y)0.25
    50-Day Average$204.39
    200-Day Average$98.09
    52-Week Range$22.28 to $280.80
    RSI (14 Days)44.4
    Average Volume (20 Days)13.83M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.62x current liabilities, and total debt is 0.52x shareholder equity.

    Current Ratio3.62x
    Quick Ratio3.47x
    Debt / Equity0.52x

    Returns and Efficiency

    Return on invested capital is -28.89% over the last 12 months, against a 5-year average of -33.36%.

    Return on Equity (ROE)-40.79%
    Return on Assets (ROA)-20.71%
    Return on Invested Capital (ROIC)-28.89%
    ROE (5Y Average)6.13%
    ROA (5Y Average)1.63%
    ROIC (5Y Average)-33.36%
    Asset Turnover0.20x
    Inventory Turnover6.13x
    Receivables Turnover3.65x
    Cash Conversion Cycle117 days

    Scores

    MRNA has an Altman Z-Score of 7.98, in the safe zone above 2.99, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score7.98
    Altman Z ZoneSafe
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $2.52B over the last 12 months is up 13.13% from the 12 months before.

    Revenue$2.52B
    Revenue Growth (YoY)+13.13%
    Gross Profit$707.00M
    Operating Income-$2.93B
    Pretax Income-$2.73B
    Net Income-$2.79B
    Reported EPS (TTM)-$7.10

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 50.78% of the $13.47B in total assets.

    Cash and Equivalents$1.20B
    Total Debt$3.55B
    Net Debt$2.35B
    Net Debt Per Share$5.87
    Working Capital$5.32B
    Shareholder Equity$6.84B
    Book Value Per Share$17.05
    Total Assets$13.47B
    Total Liabilities$6.63B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $185.00M of capital spending, operating cash flow left -$1.97B of free cash flow.

    Operating Cash Flow-$1.78B
    Capital Expenditures$185.00M
    Free Cash Flow-$1.97B
    FCF Per Share-$4.93
    Depreciation and Amortization$303.00M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -116.04%, against a 5-year average of -44.21%.

    Gross Margin28.00%
    Operating Margin-116.04%
    Pretax Margin-108.08%
    Net Margin-110.46%
    FCF Margin-78.02%
    Gross Margin (5Y Average)59.86%
    Operating Margin (5Y Average)-44.21%
    Net Margin (5Y Average)-42.92%

    Growth

    Revenue fell 53.44% a year over 3 years.

    Revenue Growth (3Y CAGR)-53.44%
    Revenue Growth (5Y CAGR)+19.34%
    Book Value Per Share Growth (2Y CAGR)-20.68%
    Tangible Book Per Share Growth (2Y CAGR)-20.68%

    Revenue and profit by year

    Dividends and Yields

    MRNA does not pay a dividend. Its free cash flow yield is -2.38%.

    FCF Yield-2.38%
    Buyback Yield-0.23%
    Shareholder Yield-0.23%

    Peer Position

    Against 12 similar companies, MRNA has the 3rd highest P/S.

    P/S Ratio32.8x vs 11.1x median
    ROIC-28.89% vs 6.17% median
    Revenue Growth (Trailing 4 Quarters, YoY)+13.13% vs +18.59% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 16.28% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+16.28%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About MRNA

    What is MRNA's market cap?

    Moderna has a market cap of $87.10B. Its enterprise value, which adds debt and subtracts cash, is $89.46B.

    How many shares of MRNA are outstanding?

    Moderna has 401.00M shares outstanding. The count is up 2.82% from a year earlier.

    Does MRNA pay a dividend?

    No. Moderna does not pay a dividend.

    How much debt does MRNA have?

    Moderna has $3.55B of total debt and $1.20B of cash and equivalents, a net debt position of $2.35B.